Literature DB >> 9052745

Microsatellite instability in cervical and endometrial carcinomas.

A Helland1, A L Børresen-Dale, P Peltomäki, M Hektoen, G B Kristensen, J M Nesland, A de la Chapelle, R A Lothe.   

Abstract

Microsatellite instability has been found preferentially in tumours associated with the hereditary non-polyposis-colorectal-cancer (HNPCC) syndrome. This phenotype, manifested as new alleles at microsatellite loci, and often the result of a defective mismatch-repair gene, is seen as allelic mobility shifts during electrophoretic runs. We examined possible alterations at 8 dinucleotide loci mapping to 6 different chromosomes in endometrial cancers (n = 20) and cervical cancers (n = 82). Overall instability was found in 30% of the endometrial cancers and in 6% of the cervical cancers, including 3 (15%) and 2 (2%) tumours, respectively, unstable at more than one locus. In contrast to the endometrial cancer sub-group, the affected cervical cancers were characterized by one or two new alleles at one or few loci. By DNA ploidy measurements 5 diploid endometrial cancers were microsatellite-unstable vs. one diploid of 6 unaltered cases (p = 0.015; Fisher's exact test). Our data confirm that a sub-set of diploid sporadic endometrial cancers are characterized by a mutator phenotype similar to that found in colorectal cancer. In contrast, among cervical cancers, not characterized by the HNPCC-tumour spectrum, this mutator phenotype is seen infrequently, and positive cases appear to display only minor alterations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052745     DOI: 10.1002/(sici)1097-0215(19970304)70:5<499::aid-ijc1>3.0.co;2-t

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Absence of microsatellite instability in mucinous carcinomas of the breast.

Authors:  Magali Lacroix-Triki; Maryou B Lambros; Felipe C Geyer; Paula H Suarez; Jorge S Reis-Filho; Britta Weigelt
Journal:  Int J Clin Exp Pathol       Date:  2010-11-27

Review 2.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

Review 3.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

4.  Microsatellite instability is absent in liver and biliary mucosa of patients with primary sclerosing cholangitis.

Authors:  S Y Jin; A E Noffsinger; P Bejarano; F L Weber; D W Hanto; J M Belli; C M Fenoglio-Preiser
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

5.  Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.

Authors:  E R Nijhuis; H W Nijman; K A Oien; A Bell; K A ten Hoor; N Reesink-Peters; H M Boezen; H Hollema; A G J van der Zee
Journal:  J Clin Pathol       Date:  2007-07       Impact factor: 3.411

6.  Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model.

Authors:  Hong Wang; Ayesha Joshi; Lori Iaconis; Garron J Solomon; Zhaoying Xiang; Harold G Verhage; Wayne Douglas; Brigitte M Ronnett; Lora Hedrick Ellenson
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 7.  The molecular genetics of cervical carcinoma.

Authors:  P A Lazo
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

8.  Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.

Authors:  Mikko Loukovaara; Annukka Pasanen; Ralf Bützow
Journal:  Cancer Med       Date:  2021-01-15       Impact factor: 4.452

9.  Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome.

Authors:  Gopeshwar Narayan; Hugo Arias-Pulido; Sanjay Koul; Hernan Vargas; Fang F Zhang; Jeannine Villella; Achim Schneider; Mary B Terry; Mahesh Mansukhani; Vundavalli V Murty
Journal:  Mol Cancer       Date:  2003-05-13       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.